Aviado · Research
Longevity Daily
Saturday, June 27, 2026
Listen
Today's Brief
Today's edition is anchored by a striking finding on glucosamine: strong genetic evidence from a large Mendelian randomization study links the common joint supplement to up to 27% lower dementia risk — an actionable data point for anyone thinking about cognitive protection. Wearable fitness trackers and routine eye exams are emerging as surprisingly powerful dementia risk tools, per new research in JAMA Neurology and the Journal of Alzheimer's Disease. On the research front, five mechanistically distinct longevity drugs appear to converge on shared metabolic pathways in mice, while Fight Aging! maps every intervention proven to lower epigenetic age in humans. Aviado Research breaks down krill oil's precise triglyceride effect — and gives you a 12-week test to know if it's actually working for you.
10 stories4 peer-reviewed1 Aviado original
Cognitive Health & Neuroprotection
Up to 27% Lower Dementia Risk: Strong Genetic Evidence Puts Glucosamine in the Spotlight
A large Mendelian randomization study -- which uses genetic variants to simulate long-term randomized assignment -- found that people with genetically predicted higher glucosamine use had up to a 27% lower risk of developing dementia. This approach significantly reduces the confounding that plagues observational supplement studies, making the finding more credible than a typical epidemiological association. Glucosamine, already widely taken for joint pain at costs under $25/month, appears to exert neuroprotective effects likely through anti-inflammatory pathways. If you have a family history of dementia and elevated inflammatory markers, this is one of the most actionable low-cost supplement signals to emerge this year -- though randomized trials are still needed to confirm causality.
Read more →Your Fitness Tracker Could Predict Dementia Years Before Symptoms Appear
Wearable accelerometer data capturing daytime activity levels, sleep patterns, and chronotype were independently associated with future dementia risk -- and improved risk prediction beyond established factors like age, genetics, and cardiovascular health -- according to a study published in JAMA Neurology. This means the movement and sleep data your smartwatch already collects may contain early cognitive warning signals most clinicians aren't yet acting on. Consider reviewing your longitudinal activity and sleep trends with a physician focused on cognitive health.
Read more →A Standard Eye Exam May Flag Alzheimer's Risk -- No Brain Scan Required
Colored fundus photography -- a routine photographic eye exam already used to screen for diabetic retinopathy -- can identify retinal regions linked to Alzheimer's disease risk factors, per a study in the Journal of Alzheimer's Disease. Because the retina shares neural tissue with the brain, vascular and structural changes visible in the eye may mirror early neurodegeneration undetectable by other means. This non-invasive and widely available tool could eventually become a front-line cognitive risk screen, especially in settings without access to PET imaging or spinal fluid biomarkers.
Read more →Supplements & Compounds
Krill Oil Reliably Cuts Triglycerides--But Leaves Cholesterol Untouched
Across multiple high-quality studies, krill oil consistently lowers blood triglycerides but barely moves LDL or HDL cholesterol -- making it one of the few supplements where you can objectively test whether it's working for you. At 2-4 grams daily split across meals, you should see a 10-23 mg/dL triglyceride drop within 12 weeks; no response by then likely means you're a non-responder regardless of dose or duration. Aviado Research walks through the evidence and lays out the exact blood test protocol to confirm your personal response.
Read the full Aviado analysis →25 Years of U.S. Supplement Data: What Gained Ground -- and What Quietly Disappeared
A sweeping analysis of U.S. consumer supplement use from 1999 through today found that the long-term rise in usage was largely driven by a sharp increase beginning around 2009-2010, not a steady climb across the full period. Trace minerals like vanadium, nickel, tin, and silicon declined significantly -- likely due to accumulating safety concerns and thin efficacy data -- while other categories grew. For supplement optimizers, this dataset is a useful filter: products that have lost consumer adoption over 25 years often did so for good scientific reasons.
Read more →Research & Papers
The Full Scorecard: Every Intervention Proven to Lower Epigenetic Age in Humans
Fight Aging! has compiled a practical, sourced list of interventions shown in human studies to measurably reduce epigenetic age -- from lifestyle modifications to pharmaceuticals. Epigenetic clocks measure biological aging at the DNA methylation level, and human data (not just mouse data) on these interventions is still surprisingly sparse; this list clarifies what has actually cleared the bar. For anyone building a longevity protocol around trackable biomarkers, this is a useful prioritization framework.
Read more →Five Different Anti-Aging Treatments Produce the Same Metabolic Fingerprint in Mice
Rapamycin, acarbose, 17α-estradiol, canagliflozin, and caloric restriction -- five mechanistically distinct longevity interventions -- produce partly overlapping metabolic signatures across seven mouse tissues, suggesting they may converge on shared upstream aging pathways. The finding raises an intriguing possibility: a single common mechanism could underlie much of what makes these treatments extend lifespan. Important caveat -- this is mouse data, and metabolic convergence in rodents doesn't guarantee the same picture in humans.
Read more →Industry & Policy
New Expert Panel Pushes Omega-3 Guidelines as Official U.S.-Canada Review Stalls
A new systematic review on omega-3 dosing recommendations is set to be unveiled at the American Society for Nutrition's annual meeting in Washington, D.C. this July -- arriving precisely as a planned joint U.S.-Canada dietary reference intake review for omega-3s has been paused, leaving current guidance in a gap. The incoming recommendation could be the most significant reset of omega-3 guidance in years. Anyone currently dosing fish oil by outdated benchmarks should watch for July's announcement.
Read more →